MedTrace Logo

Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

NCT05182957 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2026-05-01

No results posted yet for this study

Summary

Aim of this study will evaluate the Efficacy and Safety of Anti-PD-1 monoclonal antibody Combined Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma Patients.

Conditions

  • Relapsed/Refractory Peripheral T-cell Lymphoma

Interventions

DRUG

Anti-PD-1 monoclonal antibody

Anti-PD-1 monoclonal antibody, 200mg i.v d1 (/21d)

DRUG

Lenalidomide

Lenalidomide 25mg qd po d1-d10 (/21d)

DRUG

Azacitidine

Azacitidine 75mg/m2 i.v d1-d7 (/21d)

Sponsors & Collaborators

  • The First Affiliated Hospital of Soochow University

    lead OTHER

Principal Investigators

  • Depei Wu, M.D · The First Affiliated Hospital of Soochow University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2023-12-15
Completion
2026-06-15

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05182957 on ClinicalTrials.gov